Shares of Corbus Pharmaceuticals Holdings Inc. CRBP tumbled 10.22% to $8.78 Tuesday, on what proved to be an all-around mixed ...

Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”), today announced that the abstract for its ...

This was the stock's third consecutive day of losses.

HC Wainwright reaffirmed their buy rating on shares of Corbus Pharmaceuticals (NASDAQ:CRBP – Free Report) in a research ...

Corbus Pharmaceuticals (CRBP) announced that the abstract for its first-in-human dose escalation clinical study conducted in the United States ...

In a report released on February 7, Andrew Fein from H.C. Wainwright maintained a Buy rating on Corbus Pharmaceuticals (CRBP – Research ...

NORWOOD, Mass. - Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP), a $119 million market cap biopharmaceutical company, announced the release of an abstract detailing its Phase 1 clinical study of ...

Corbus Pharmaceuticals Holdings Inc. (NASDAQ:CRBP) stock has reached a 52-week low, trading at $9.1, reflecting a period of significant pressure for the biopharmaceutical company. With a market ...

Detailed price information for Corbus Pharmaceuticals Hldgs Inc (CRBP-Q) from The Globe and Mail including charting and trades.

To read more about the latest highlights related to the PDC market, get a snapshot of the key highlights entailed in the ...